TB Archives – Page 5 of 49 – Treatment Action Group

TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023

September 27, 2023
Dorrit Walsh

TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member…

TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR

September 22, 2023
Dorrit Walsh

TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from $14.25 to $9.99 for a three-month patient course.

New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN

September 20, 2023
Dorrit Walsh

As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.

At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens

September 19, 2023
Dorrit Walsh

Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6x24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

TAG Reaction to the Price of GeneXpert Tests

September 19, 2023
Dorrit Walsh

Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing major gaps in TB diagnosis.

Far Off Track: Funding for TB Research, 2018 – 2022

September 19, 2023
Dorrit Walsh

United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to…

TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023

September 12, 2023
Dorrit Walsh

Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV, TB, and HCV.

Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%

August 16, 2023
Dorrit Walsh

In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.

Letter to Dr. Jeanne Marazzo, New Director NIAID

August 10, 2023
Dorrit Walsh

We're excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).

Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply

August 1, 2023
Dorrit Walsh

TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.